These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 19657721)
21. Molecular Epidemiology and Risk Factors of Yang Z; Huang Q; Qin J; Zhang X; Jian Y; Lv H; Liu Q; Li M Front Cell Infect Microbiol; 2020; 10():578098. PubMed ID: 33425775 [TBL] [Abstract][Full Text] [Related]
22. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. Polivkova S; Krutova M; Capek V; Sykorova B; Benes J Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906 [TBL] [Abstract][Full Text] [Related]
23. Association Between Antibiotic Use and Hospital-onset Clostridioides difficile Infection in US Acute Care Hospitals, 2006-2012: An Ecologic Analysis. Kazakova SV; Baggs J; McDonald LC; Yi SH; Hatfield KM; Guh A; Reddy SC; Jernigan JA Clin Infect Dis; 2020 Jan; 70(1):11-18. PubMed ID: 30820545 [TBL] [Abstract][Full Text] [Related]
25. Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. Jardin CG; Palmer HR; Shah DN; Le F; Beyda ND; Jiang Z; Garey KW J Hosp Infect; 2013 Sep; 85(1):28-32. PubMed ID: 23834988 [TBL] [Abstract][Full Text] [Related]
26. Challenges and opportunities in the management of Clostridium difficile infection. DuPont HL Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):863-74. PubMed ID: 25012255 [TBL] [Abstract][Full Text] [Related]
27. Rifaximin in the treatment of recurrent Clostridium difficile infection. Mattila E; Arkkila P; Mattila PS; Tarkka E; Tissari P; Anttila VJ Aliment Pharmacol Ther; 2013 Jan; 37(1):122-8. PubMed ID: 23095030 [TBL] [Abstract][Full Text] [Related]
28. Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). Bouza E; Aguado JM; Alcalá L; Almirante B; Alonso-Fernández P; Borges M; Cobo J; Guardiola J; Horcajada JP; Maseda E; Mensa J; Merchante N; Muñoz P; Pérez Sáenz JL; Pujol M; Reigadas E; Salavert M; Barberán J Rev Esp Quimioter; 2020 Apr; 33(2):151-175. PubMed ID: 32080996 [TBL] [Abstract][Full Text] [Related]
29. Clostridium difficile: A Frequent Infection in Children After Intestinal Transplantation. Duclaux-Loras R; Berthiller J; Ferroni A; Chardot C; Goulet O; Lacaille F; Norsa L Transplantation; 2020 Jan; 104(1):197-200. PubMed ID: 31205257 [TBL] [Abstract][Full Text] [Related]
30. Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients. Miller R; Morillas JA; Brizendine KD; Fraser TG J Clin Microbiol; 2020 Feb; 58(3):. PubMed ID: 31896665 [TBL] [Abstract][Full Text] [Related]
31. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis. Sholeh M; Krutova M; Forouzesh M; Mironov S; Sadeghifard N; Molaeipour L; Maleki A; Kouhsari E Antimicrob Resist Infect Control; 2020 Sep; 9(1):158. PubMed ID: 32977835 [TBL] [Abstract][Full Text] [Related]
32. A systematic review of the use of rifaximin for Clostridium difficile infections. Ng QX; Loke W; Foo NX; Mo Y; Yeo WS; Soh AYS Anaerobe; 2019 Feb; 55():35-39. PubMed ID: 30391527 [TBL] [Abstract][Full Text] [Related]
33. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection. Bass SN; Bauer SR; Neuner EA; Lam SW J Hosp Infect; 2013 Sep; 85(1):22-7. PubMed ID: 23876778 [TBL] [Abstract][Full Text] [Related]
34. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy. Bouza E; Alcalá L; Marín M; Valerio M; Reigadas E; Muñoz P; González-Del Vecchio M; de Egea V Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1777-1786. PubMed ID: 28501926 [TBL] [Abstract][Full Text] [Related]
35. The association of a reduced susceptibility to moxifloxacin in causative Clostridium (Clostridioides) difficile strain with the clinical outcome of patients. Krutova M; Capek V; Nycova E; Vojackova S; Balejova M; Geigerova L; Tejkalova R; Havlinova L; Vagnerova I; Cermak P; Ryskova L; Jezek P; Zamazalova D; Vesela D; Kucharova A; Nemcova D; Curdova M; Nyc O; Drevinek P Antimicrob Resist Infect Control; 2020 Jun; 9(1):98. PubMed ID: 32605598 [TBL] [Abstract][Full Text] [Related]
36. Prevalence, characteristics and antimicrobial susceptibility patterns of Clostridioides difficile isolated from hospitals in Iran. Alimolaei M; Rahimi HR; Ezatkhah M; Shamsaddini Bafti M; Afzali S J Glob Antimicrob Resist; 2019 Dec; 19():22-27. PubMed ID: 30825696 [TBL] [Abstract][Full Text] [Related]